Briacell Therapeutics (BCTX)

• Market cap: $25.2M
• 1 day: 3.79%
• 5 days: 5.24%
• 1 month: -13.75%
• 3 months: -29.18%
• 6 months: -69.06%
• Year to date: -58.02%
• 1 year: -89.55%
• 5 years: -99.62%
• 10 years: -99.49%
• Sector: Healthcare
• Industry: Biotechnology

About: BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Employees: 4